Systemic administration of interleukin-12 can restore the anti-tumor potential of B16 melanoma-draining lymph node cells impaired at a late tumor-bearing state

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.

1989 • 1,989 citations

Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.

1993 • 1,704 citations

Antitumor and antimetastatic activity of interleukin 12 against murine tumors.

1993 • 1,206 citations

Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers.

1991 • 976 citations

Interleukin-12 and its role in the generation of TH1 cells

1993 • 869 citations

Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.

1994 • 796 citations

Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells.

1990 • 679 citations

Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs

1977 • 662 citations

Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor).

1991 • 471 citations

Lymphadenectomy in the Management of Stage I Malignant Melanoma: A Prospective Randomized Study

1986 • 402 citations

Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.

1992 • 369 citations

A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (Stage I) Melanoma Treated in Alabama, USA, and New South Wales, Australia

1982 • 354 citations

Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells.

1992 • 333 citations

Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.

1991 • 217 citations

Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.

1995 • 206 citations

Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells

1995 • 202 citations

Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: Results of surgical treatment in 1319 patients

1982 • 177 citations

Surgical Management of Regional Lymph Nodes in Patients with Melanoma Experience with 4682 Patients

1994 • 169 citations

Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12.

1996 • 166 citations

Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes.

1995 • 138 citations

Local injection of OK432 can augment the TH1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential

1997 • 23 citations

Specific immunotherapy with tumour‐draining lymph node cells cultured with both anti‐CD3 and anti‐CD28 monoclonal antibodies

1996 • 15 citations

The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells

1995 • 13 citations